LGC expands SARS-CoV-2 serology offering with 11-member positive-patient Performance Panel

LGC has released the AccuSet™ SARS-CoV-2 Performance Panel (material #0820-0410), intended for use by clinical laboratories and diagnostic manufacturers alike, to evaluate SARS-CoV-2 antibody assays.  This eleven-member validation panel contains highly characterised, true patient specimens, offering an out-of-the-box solution to provide confidence, mitigate sourcing challenges and accelerate antibody assay development, validation, verification and onboarding.

Comprised of undiluted, naturally occurring human plasma samples, this panel demonstrates a range of SARS-CoV-2 antibody reactivity. Ten panel members represent collections from multiple individuals positive for antibodies to SARS-CoV-2; a single negative member is also included. A comprehensive data sheet, generated using commercially available SARS-CoV-2 antibody assays, is provided for comparative analysis.

Michael Sweatt, Executive Vice President, LGC SeraCare, stated, “Whether generating validation data for a regulatory submission, or performing assay verification in a clinical laboratory setting, LGC SeraCare’s panel products offer a comprehensive solution to rigorously evaluate your assay. Our suite of products will allow you to confidently develop, challenge, troubleshoot, verify, and validate your assay from initial proof of concept through production and onboarding into the clinical laboratory.”